Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

MeSH terms

• Advisory Committees*
• American Cancer Society
• American Heart Association
• Androgen Antagonists / adverse effects*
• Androgen Antagonists / therapeutic use*
• Cardiovascular Diseases / epidemiology*
• Gonadotropin-Releasing Hormone / agonists
• Humans
• Male
• Prostatic Neoplasms / drug therapy*
• Risk Factors
• Societies, Medical*
• United States